AI Summary AFP-L3 is a blood test that helps watch for hepatocellular carcinoma (HCC), the most common primary liver cancer, in people at high risk, such as those with cirrhosis. Doctors use it with a liver ultrasound, alongside AFP and DCP. A high result raises suspicion but does not diagnose cancer. Contrast-enhanced CT or MRI, or sometimes a biopsy, confirms it. Ask your care team which markers and schedule fit you.
Source: www.liverdirectory.com
Medically Reviewed.
The AFP-L3 test is a blood test used to help watch for hepatocellular carcinoma (HCC), the most common type of primary liver cancer. It is a tumor marker, meaning a substance that can change in the blood when a cancer is present.
Doctors use AFP-L3 together with a liver ultrasound, not on its own. A high result raises suspicion but does not diagnose cancer. Imaging, and sometimes a biopsy, confirm it.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
LIVER CANCER TUMOR MARKER
The AFP-L3 test measures a form of alpha-fetoprotein (AFP) in a sample of your blood. It is a routine blood draw. AFP-L3 is one of three tumor markers doctors use for liver cancer. The other two are AFP and des-gamma-carboxy prothrombin (DCP, also called PIVKA-II).
Early liver cancer often causes no symptoms. Testing on a schedule can help find a problem before you feel it. That is why doctors order tumor markers for people whose liver disease puts them at high risk of HCC.
AFP-L3 is a clue, not a verdict. Doctors advise against using biomarkers alone, including AFP, to diagnose HCC, because they are not accurate enough. Your care team reads the result together with your imaging, your liver disease, and your symptoms.
WHO GETS TESTED
Tumor marker testing is for people whose liver disease raises their risk of HCC. Your schedule depends on your condition and your care team's plan.
Guidelines call for regular HCC surveillance in people at high risk. The core tools are a liver ultrasound, often with an AFP blood test, about every six months. Your doctor decides whether AFP-L3 or DCP is added to that plan.
After a previous HCC, the risk of a new tumor is much higher. Guidance calls for checks every 4 months. Each visit includes an abdominal ultrasound and tumor markers such as AFP, AFP-L3, and/or DCP.
Cure of hepatitis C with antiviral treatment lowers risk but does not remove it, especially if you already have advanced scarring. The follow-up schedule depends on how long ago treatment ended and how severe your liver disease was.
Guidelines recommend against surveillance in people with Child-Turcotte-Pugh C cirrhosis who cannot have a liver transplant. They also recommend against it when another serious illness limits life expectancy to under 1 to 2 years and cannot be treated by transplant or other directed therapy.
AFP-L3 VS. OTHER MARKERS
No single blood marker is perfect. Doctors choose tests to fit the person, and they never rely on a blood marker alone.
Both tests look at alpha-fetoprotein. Adding an AFP test to ultrasound finds more early-stage HCC but lowers specificity, which means more false alarms. Read more on the AFP page.
DCP is a separate tumor marker. AFP, AFP-L3, and DCP are listed together for monitoring after a previous HCC. Markers other than AFP show promise but lack enough long-term data to replace ultrasound for routine screening.
A blood marker cannot replace a scan. HCC is diagnosed with contrast-enhanced CT or MRI, using signs called arterial phase hyperenhancement and washout. A liver ultrasound is the standard surveillance scan.
Some scores combine several markers into one number to estimate liver cancer risk. The GALAD score is one example.
UNDERSTANDING TEST RESULTS
Labs report AFP-L3 in different ways, and reference ranges vary by lab and test method. Use the range printed on your own report, and ask your care team how they read it.
A result in the usual range does not rule out liver cancer. Your ultrasound and your schedule of repeat checks still matter.
A result above the range raises suspicion. It can also be a false alarm, because markers lose specificity. It is a reason for closer follow-up, not a diagnosis.
A change over time can matter as much as one number. Your team may compare results across several visits.
AFP can also help judge an indeterminate liver nodule, which is a spot on imaging that is not clearly cancer. A raised AFP can prompt closer imaging or a biopsy.
FOLLOW-UP AFTER A HIGH RESULT
A high AFP-L3 result is a signal to look closer. It is not a cancer diagnosis. These steps show how care usually moves forward.
DOCTOR VISIT CHECKLIST
Clear questions help you get the most from your visit. Write down the answers so you can share them with family.
A balanced, liver-friendly diet supports your liver, helps manage weight and blood sugar, and lowers the risk of other health problems during long-term follow-up.
Explore Liver DietThe Amsety Bar is a liver-friendly snack or meal replacement that can make it easier to eat well on busy days.
Shop Amsety Bars
Common Questions
No. A high AFP-L3 result raises suspicion but does not diagnose liver cancer. Blood markers on their own are not accurate enough to diagnose HCC, and a high result can be a false alarm. Doctors confirm HCC with contrast-enhanced CT or MRI, looking for two signs called arterial phase hyperenhancement and washout. If imaging is unclear, a biopsy may be used. Your care team reads the result together with your imaging, your liver disease, and your symptoms. A high result is a reason for closer follow-up, not a diagnosis.
Not on its own. A blood marker cannot replace a scan, and a liver ultrasound is the standard surveillance scan. For people with cirrhosis, the usual check is a liver ultrasound about every six months, often with an AFP blood test. Your doctor may add AFP-L3 or DCP to that plan. After a previous HCC, AFP-L3 is one of the markers that can be paired with an ultrasound every 4 months. Markers other than AFP show promise, but they lack enough long-term data to replace ultrasound for routine screening.
It depends on your plan, your condition, and your care team's advice. After a previous HCC, guidance calls for checks every 4 months. Each visit includes an abdominal ultrasound and tumor markers such as AFP, AFP-L3, and/or DCP. For most people with cirrhosis, guidelines describe checks about every six months. Not everyone gets AFP-L3. Ask your care team which markers are on your plan and when your next test is due.
AFP-L3 is a form of alpha-fetoprotein (AFP). Both are tumor markers, which means substances that can change in the blood when a cancer is present. AFP is the more widely used test. Doctors use AFP-L3 alongside it. Adding AFP to ultrasound finds more early-stage HCC, but it lowers specificity, which means more false alarms. No single marker is perfect, so doctors choose tests to fit each person. Read more on the AFP page to see how the two tests compare.
No special preparation, such as fasting, is listed for this test. It is a routine blood draw. Instructions can differ from lab to lab, so ask your care team or the lab before your visit. Also ask which reference range the lab uses, because ranges vary by lab and test method.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
